Copenhagen, 10 November 2009 - NeuroSearch's (NEUR.CO) Q3 interim report 2009
will be on the agenda of a Board meeting scheduled for 16 November 2009 and be
released immediately hereafter.

On the same day, a teleconference will be held at 3 pm Copenhagen time (2 pm
London time, 9 am New York time) where Flemming Pedersen, CEO, Anita Milland,
Vice President & CFO and Hanne Leth Hillman, Vice President & Director of
Investor & Capital Market Relations, will present the Q3 interim report 2009
and answer questions. The teleconference will be conducted in English and the
telephone number is +44 (0) 20 7162 0077. The corresponding PowerPoint
presentation will be available at www.neurosearch.com.



Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103



About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. The drug
pipeline comprises eight clinical (Phase I-III) development programmes:
Huntexil® (pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias
in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase
I) and NSD-721 for social anxiety disorder (Phase I) in partnership with GSK.
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates
and holds equity interests in several biotech companies.

presse.12.09 - q3 release date - uk.pdf